Citigroup Inc. recorded Novavax, Inc. (NASDAQ:NVAX), reducing its target price to $1.50 today
- Updated: September 16, 2016
Citigroup Inc. lowered the price target of Novavax, Inc. (NASDAQ:NVAX) to $2, reporting a possible downside of -0.82%.
On 8/23/2016, Vetr Inc. released a statement on Novavax, Inc.(NASDAQ:NVAX) raised the target price from $0.00 to $8.66. At the time, this suggested an upside of 0.17%.
Boasting a price of $8.34, Novavax, Inc. (NASDAQ:NVAX) traded 0.36% higher on the day. The last close is up 33.70% from the 200-day moving average, compared with the S&P 500 Index which has decreased -0.01% over the same time. NVAX has been tracking to a 50-day average of $7.35 and 200-day moving average of $6.24. Trading volume was was up over the average, with 25,965,663 shares of NVAX changing hands over the typical 5,016,980 shares.
Recent Performance Chart:
Novavax, Inc. has a one-year low of $4.08 and a one-year high of $10.70 and has a total market value of $0.0.
A total of 8 equity analysts have released a research note on NVAX. Five firms rate the company a strong buy, three analysts rate the company a buy, 0 analysts rate the company a hold, 0 rate the stock to underperform, and lastly 0 brokeragesrate the company as sell with a 12-month target of $15.39
More About Novavax, Inc. (NASDAQ:NVAX)
Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, and including Middle East respiratory syndrome (MERS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.